argenx SE · Healthcare
Paid for today, but breaks on a small cut — or only looks over-priced at a 9% discount rate.
At a 25.0% margin the price requires 19.9% 3y revenue CAGR against 31.4% consensus, a cushion of -0.9pt versus a 0pt correction cut. Cushion is negative at the panel margin but turns positive 1pt lower in the discount rate, so it hangs on the rate and the margin. Growth biotech de-rates with risk-off; fundamentals untouched by AI.
Would recover if: the cash-conversion gap (cash margin 0.8% vs 32.5% consensus) proves real rather than tax/WC timing. We re-check this against analyst estimates every evening.
10 years, at a 25% margin (analysts' margin, cut for cash conversion)
+19.4%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
25 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 0% of reported profit arrived as operating cash, so the test cuts the analysts' 32% margin to 16%. That leaves a cushion of −11pt instead of +5pt, and the smaller of the two decides the group. Two or more red flags: this name cannot come out on top, however large its cushion.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 23, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the 20th percentile of published models, 16% below the median, meaning the market has heard the bull case for myositis and the Forte acquisition but largely declines to pay for it.
Does the ALKIVIA myositis launch actually accelerate prescription volumes above the decelerating baseline the price assumes, and our wired data can measure unit volumes to settle it.
What the price refuses to pay for, and the full reconstruction, on the ARGX quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names